Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The company granted stock options to purchase an aggregate of 87,950 shares of Nurix common stock and restricted stock unit awards (RSUs) representing an aggregate of 60,050 shares of Nurix common stock.
One fourth of the total number of shares underlying the stock options will vest on the one-year anniversary of the employee's date of hire and one forty-eighth of the total number of shares underlying the stock options will vest each month thereafter until the stock option is fully vested on the fourth anniversary of the employee's date of hire, subject to the employee's continued service with Nurix on each such vesting date. The stock options have a term of ten years and an exercise price of $9.73 per share, which is equal to the closing price of Nurix's common stock on the grant date as reported by the Nasdaq Global Market.
One fourth of the total number of shares subject to the RSUs will vest on the one-year anniversary of the RSU vesting start date, which is April 30, 2025, subject to the employee's continued service with Nurix on the vesting date. Thereafter, one sixteenth of the total number of shares subject to the RSUs shall vest quarterly, until the RSU award is fully vested on the fourth anniversary of the vesting start date, subject to the employee's continued service with Nurix on each such vesting date.
About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Nurix's wholly owned, clinical stage pipeline includes degraders of Bruton's tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix's partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix's dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine's next chapter with a new script to outmatch disease. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.
Contacts:
InvestorsJason Kantor, Ph.D.Nurix Therapeutics, Inc.ir@nurixtx.com
Elizabeth Wolffe, Ph.D.Wheelhouse Life Science Advisorslwolffe@wheelhouselsa.com
MediaAljanae ReynoldsWheelhouse Life Science Advisorsareynolds@wheelhouselsa.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
What To Expect From Workday's (WDAY) Q2 Earnings
Enterprise software company Workday (NASDAQ:WDAY) will be reporting results this Thursday after market hours. Here's what investors should know. Workday beat analysts' revenue expectations by 1% last quarter, reporting revenues of $2.24 billion, up 12.6% year on year. It was a satisfactory quarter for the company, with a solid beat of analysts' EBITDA estimates but a significant miss of analysts' billings estimates. Is Workday a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Workday's revenue to grow 12.3% year on year to $2.34 billion, slowing from the 16.7% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $2.11 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Workday has a history of exceeding Wall Street's expectations, beating revenue estimates every single time over the past two years by 0.9% on average. Looking at Workday's peers in the finance and hr software segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Marqeta delivered year-on-year revenue growth of 20.1%, beating analysts' expectations by 6.9%, and Workiva reported revenues up 21.2%, topping estimates by 3%. Marqeta traded up 19.9% following the results while Workiva was also up 32.2%. Read our full analysis of Marqeta's results here and Workiva's results here. Debates around the economy's health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the finance and hr software stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.6% on average over the last month. Workday is down 1.5% during the same time and is heading into earnings with an average analyst price target of $293.69 (compared to the current share price of $230.17). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
2 hours ago
- Business Insider
US Tiger Securities Sticks to Its Buy Rating for XPeng, Inc. ADR (XPEV)
In a report released today, Bo Pei CFA from US Tiger Securities reiterated a Buy rating on XPeng, Inc. ADR, with a price target of $28.00. The company's shares closed today at $20.74. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Pei CFA is ranked #9697 out of 9921 analysts. In addition to US Tiger Securities, XPeng, Inc. ADR also received a Buy from Bank of America Securities's Ming-Hsun Lee in a report issued today. However, on August 11, Bernstein maintained a Hold rating on XPeng, Inc. ADR (NYSE: XPEV). The company has a one-year high of $27.16 and a one-year low of $6.65. Currently, XPeng, Inc. ADR has an average volume of 6.99M.
Business Insider
2 hours ago
- Business Insider
Orion Energy announces 1-for-10 reverse stock split
Orion Energy (OESX) announced that its board of directors and shareholders approved a 1-for-10 reverse stock split of the company's common stock, no par value per share, which will be effective at 12:01 a.m., Central Time, on August 22. Orion's common stock will continue to be traded on Nasdaq on a split-adjusted basis beginning on August 22 under the company's existing trading symbol. The reverse stock split is intended to increase the bid price of the company's common stock so that Orion can regain compliance with the minimum bid price requirement of $1.00 per share for continued listing on Nasdaq. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
